BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25231553)

  • 1. Prognosis and management of acute myeloid leukemia in patients with Down syndrome.
    Caldwell JT; Ge Y; Taub JW
    Expert Rev Hematol; 2014 Dec; 7(6):831-40. PubMed ID: 25231553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relapsed acute myeloid leukemia with Down syndrome showing long disease-free survival after bone marrow transplantation].
    Daifu T; Kato I; Matubara H; Abe D; Uryu K; Tokumasu M; Umeda K; Watanabe K; Izawa K; Asai K; Nakahata T; Adachi S
    Rinsho Ketsueki; 2009 Feb; 50(2):73-7. PubMed ID: 19265297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The paradox of Myeloid Leukemia associated with Down syndrome.
    Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
    Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique clinical and biological features of leukemia in Down syndrome children.
    Xavier AC; Ge Y; Taub J
    Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
    Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
    Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
    Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
    Kolb EA; Meshinchi S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():507-13. PubMed ID: 26637766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis.
    Kawamura M; Kaku H; Taketani T; Taki T; Shimada A; Hayashi Y
    Cancer Genet Cytogenet; 2008 Jan; 180(1):74-8. PubMed ID: 18068539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
    Moritake H; Yamada A; Kimoto Y; Sawa D; Shimonodan H; Nunoi H
    Am J Hematol; 2012 Apr; 87(4):447-50. PubMed ID: 22389016
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
    Hitzler J; Alonzo T; Gerbing R; Beckman A; Hirsch B; Raimondi S; Chisholm K; Viola S; Brodersen L; Loken M; Tong S; Druley T; O'Brien M; Hijiya N; Heerema-McKenney A; Wang YC; Schore R; Taub J; Gamis A; Kolb EA; Berman JN
    Blood; 2021 Dec; 138(23):2337-2346. PubMed ID: 34320162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Taga T; Tanaka S; Hasegawa D; Terui K; Toki T; Iwamoto S; Hiramatsu H; Miyamura T; Hashii Y; Moritake H; Nakayama H; Takahashi H; Shimada A; Taki T; Ito E; Hama A; Ito M; Koh K; Hasegawa D; Saito AM; Adachi S; Tomizawa D
    Leukemia; 2021 Sep; 35(9):2508-2516. PubMed ID: 33589754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
    Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
    Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction.
    Barker JA; Marini BL; Bixby D; Perissinotti AJ
    J Oncol Pharm Pract; 2016 Dec; 22(6):811-815. PubMed ID: 26471735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid leukemia in Down syndrome.
    Khan I; Malinge S; Crispino J
    Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
    Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
    Xavier AC; Ge Y; Taub JW
    J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.